Novo Nordisk A/S
Oppenheimer says investors are missing opportunities in three biotech areas and the related stocks
As biopharma investors follow the latest buzz around advancements in clinical research, they may be under-appreciating opportunities in neurology, psychiatry and genetic medicine, according to a report from Oppenheimer. Specifically, analyst Jay Olson called out companies such as Biogen , Karuna Therapeutics and Crispr Therapeutics , among others. “Our analysis shows Genetic Medicine and Metabolic […]
Read More
Eli Lilly CEO vows not to raise insulin prices again, while Novo Nordisk and Sanofi hedge
Eli Lilly CEO Dave Ricks on Wednesday promised not to raise prices on the company’s existing insulin products again — the only executive to do so before a Senate Health Committee hearing on making the life-saving diabetes drug more affordable. Sen. Bernie Sanders, the committee’s chair, asked Ricks and the CEOs of Novo Nordisk and […]
Read More
In this article are 10 worldwide stocks analyst adore coming out of the earnings 7 days, Lender of America claims
Massive European corporations noted bumper gains above the past two weeks. Nonetheless, in accordance to strategists at Financial institution of The united states, there ended up extra downward than upward revisions of organization earnings estimates by analysts. The expense bank mentioned European companies observed a lessen in their earnings for each share (EPS) revision ratio […]
Read More
Novo Nordisk cuts some U.S. supply of Wegovy being overweight drug as demand soars
Danish pharmaceutical company Novo Nordisk said Thursday it was slicing the source of starter doses of its weight problems drug Wegovy in the U.S. as it struggles to preserve up with surging demand from customers. Main Economic Officer Karsten Munk Knudsen told CNBC that halving the provide of Wegovy starter doses was supposed to make certain present patients could […]
Read More
Obesity is a chronic disease. It’s why treating it will be so profitable unless payers push back
While there has been plenty of buzz about how successful patients have been in losing weight while taking a new class of obesity medications, there is a growing realization that when people stop taking these pricey drugs, the pounds can creep back on. There was a frank discussion of this on Eli Lilly’s first-quarter earnings […]
Read More
Being overweight drug marketplace could be really worth $200 billion in the decade, states Barclays, as sector valuations grow
The burgeoning pounds-decline drug market, which is whetting investors’ appetites with its pledge of combatting worldwide being overweight rates, could be value as a great deal as $200 billion inside of the following decade, in accordance to Barclays lender. Dubbing being overweight “the story of this ten years,” Barclays’ head of European pharmaceuticals fairness investigation […]
Read More
This weight-reduction drug maker’s inventory is up 20% this 12 months — and Barclays sees it going larger
Shares of Novo Nordisk , the pharmaceutical large behind the weight-reduction drug Wegovy, are envisioned to rally by a further 20% about the next 12 months thanks to the firm’s promising pipeline of prescription drugs aimed at obesity, according to Barclays. Wegovy catapulted into the spotlight many thanks to its good results in weight decline […]
Read More
Eli Lilly says obesity drug tirzepatide resulted in weight loss of up to 34 pounds
A pharmacist displays a box of Mounjaro, a tirzepatide injection drug used for treating type 2 diabetes and made by Lilly at Rock Canyon Pharmacy in Provo, Utah, May 29, 2023. George Frey | Reuters Patients who took Eli Lilly‘s weight loss drug tirzepatide lost up to 34 pounds on average, or 16% of their […]
Read More
Eli Lilly, Novo Nordisk and Sanofi CEOs to testify before Senate on lowering insulin prices
In this photo illustration, an insulin pen manufactured by the Novo Nordisk company is displayed on March 14, 2023 in Miami, Florida. Joe Raedle | Getty Images News | Getty Images The top executives of the three drug companies that control 90% of the global insulin market will testify May 10 before the Senate Health […]
Read More
Senate legislation would cap insulin at $35 per month for people with private insurance
In this photo illustration, insulin pens manufactured by the Novo Nordisk company are displayed on March 14, 2023 in Miami, Florida. Joe Raedle | Getty Images Bipartisan Senate legislation introduced Friday would cap the price of insulin at $35 per month for people with private insurance. The bill, drafted by Sens. Jeanne Shaheen, D-N.H., and […]
Read More